ADC Therapeutics (ADCT) Net Margin (2021 - 2026)
ADC Therapeutics' (ADCT) quarterly Net Margin came in at 86.06% in Q2 2026, up 21462.0% year-over-year from N/an in Q2 2025, and up 45.57% quarter-over-quarter from 158.11% in Q1 2026.
Powered by 
Analysis
ADC Therapeutics (ADCT) Net Margin (2021 - 2026) Analysis & Trends
ADC Therapeutics has disclosed Net Margin across 6 years of filings, most recently posting 86.06% for Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.59 Bn | 192.60 Bn | 7.24 Bn | 23.62% |
| 2 | Gilead Sciences | 180.21 Bn | 177.03 Bn | 6.22 Bn | -134.51% |
| 3 | Vertex Pharmaceuticals | 131.41 Bn | 123.56 Bn | 2.84 Bn | 32.99% |
| 4 | Regeneron Pharmaceuticals | 81.94 Bn | 73.94 Bn | 3.93 Bn | 30.23% |
| 5 | Argenx Se | 60.60 Bn | 55.41 Bn | 1.37 Bn | 31.16% |
| 6 | Moderna | 53.61 Bn | 48.47 Bn | 52.00 Mn | -539.31% |
| 7 | Alnylam Pharmaceuticals | 33.49 Bn | 30.18 Bn | 992.69 Mn | 12.74% |
| 8 | Biogen | 31.83 Bn | 30.54 Bn | 1.96 Bn | 3.56% |
| 9 | Roivant Sciences | 29.14 Bn | 29.14 Bn | 1.16 Mn | -20,152.98% |
| 10 | ADC Therapeutics | 173.62 Mn | -45.49 Mn | 17.14 Mn | -86.06% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -86.06% |
| Mar 31, 2026 | -158.11% |
| Sep 30, 2025 | -249.38% |
| Jun 30, 2025 | -300.68% |
| Mar 31, 2025 | -167.59% |
| Sep 30, 2024 | -236.73% |
| Jun 30, 2024 | -206.47% |
| Mar 31, 2024 | -254.81% |
| Sep 30, 2023 | -312.58% |
| Jun 30, 2023 | -249.96% |
| Mar 31, 2023 | -312.90% |
| Sep 30, 2022 | -66.31% |
| Jun 30, 2022 | -372.30% |
| Mar 31, 2022 | -35.83% |
| Sep 30, 2021 | -544.22% |
| Jun 30, 2021 | -1,930.03% |